Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult)

Key Inclusion Criteria: * Male and female patients between 30-70 years of age diagnosed with type 2 diabetes within 5 years * Presence of GAD65 antibodies * Detectable C-peptide level * Patients requiring treatment with diet and/or oral hypoglycaemic agents (OHA) * Written informed Consent Key Exclusion Criteria: * Treatment with insulin * Intolerance to OHA * Secondary diabetes mellitus * History of certain diseases or conditions (e.g. anaemia, epilepsy, head trauma, neurological disease, alcohol or drug abuse, HIV, hepatitis) * Treatment with any vaccine within one month prior to first Diamyd® dose or planned treatment with vaccine up to 2 months after the second Diamyd® dose * Participation in other clinical trials with a new chemical entity within the previous 3 months * Pregnancy (or planned pregnancy within one year after 2nd administration) * Presence of associated serious disease or condition which in the opinion of the investigator makes the patient non-eligible for the study * Significant illness other than diabetes within 2 weeks prior to first dosing * Unwillingness to comply with the provisions of the protocol * Clinically significant history of acute reaction to drugs in the past * Treatment with immunosuppressants